In preparation for the recent Pharma Symposium conference held in Toronto on March 31-April 1, PDCI conducted an online survey of a select group of pharmaceutical stakeholders in Canada and Europe.  The purpose of this survey was to gauge whether some of the cost containment mechanisms being implemented in certain international markets (UK, France, Italy, the US) could possibly be adopted by public and private payers in other markets – including Canada.  The survey respondents were not asked to provide their names but only identified their location and which stakeholder group they were affiliated with (e.g. industry, public payer, private payer).

Over the coming weeks, we will be issuing a series of issue papers focusing on the following topics about which participants were asked to share their insights:

• Delisting of Oncology Treatments
• Off-Label Prescribing Regulations
• Downgrading of Benefits
• Uptake of Biosimilars
• Private Payer Exclusivity Agreements

Please click here for a complimentary copy of the first issue paper on ‘Delisting of Oncology Treatments.’

If you have any questions regarding the paper, please contact Courtney Abunassar, PDCI’s Manager of Market Access and Policy Research.